Tagrisso Approved In China As A 1St-Line Treatment For Egfr-Mutated Non-Small Cell Lung Cancer
Astrazeneca Today Announced That It Has Received Marketing Authorisation From China'S National Medical Products Administration (Nmpa) For Tagrisso (Osimertinib) As A 1St-Line Treatment For Adults With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumours Have The Genetic Mutations Of Epidermal Growth Factor Receptor (Egfr) Exon 19 Deletions Or Exon 21 (L858R) Substitutions.The Approval Followed The Priority Review Pathway And Is Based On Results From The Phase Iii Flaura Trial, Which Were Published In The New England Journal Of Medicine.Dave Fredrickson, Executive Vice President, Oncology, Said:
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
